Agios Pharmaceuticals Stock Shares Outstanding
| 8AP Stock | EUR 51.00 1.60 3.24% |
Agios Pharmaceuticals fundamentals help investors to digest information that contributes to Agios Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Agios Stock. The fundamental analysis module provides a way to measure Agios Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Agios Pharmaceuticals stock.
Agios |
Agios Pharmaceuticals Company Shares Outstanding Analysis
Agios Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Agios Pharmaceuticals Shares Outstanding | 54.94 M |
Most of Agios Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Agios Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Agios Pharmaceuticals has 54.94 M of shares currently outstending. This is 69.57% lower than that of the Healthcare sector and 48.58% lower than that of the Biotechnology industry. The shares outstanding for all Germany stocks is 90.39% higher than that of the company.
Agios Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Agios Pharmaceuticals' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Agios Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Agios Pharmaceuticals by comparing valuation metrics of similar companies.Agios Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.
Agios Fundamentals
| Return On Equity | -0.2 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (18.34) % | |||
| Current Valuation | 1.01 B | |||
| Shares Outstanding | 54.94 M | |||
| Shares Owned By Insiders | 1.34 % | |||
| Shares Owned By Institutions | 98.67 % | |||
| Price To Earning | (9.13) X | |||
| Price To Book | 1.62 X | |||
| Price To Sales | 159.36 X | |||
| Revenue | 14.24 M | |||
| Gross Profit | 140.39 M | |||
| EBITDA | (380.48 M) | |||
| Net Income | (231.8 M) | |||
| Cash And Equivalents | 495.39 M | |||
| Cash Per Share | 8.43 X | |||
| Total Debt | 116.47 M | |||
| Debt To Equity | 21.80 % | |||
| Current Ratio | 5.96 X | |||
| Book Value Per Share | 19.13 X | |||
| Cash Flow From Operations | (309.48 M) | |||
| Earnings Per Share | (6.05) X | |||
| Target Price | 62.43 | |||
| Number Of Employees | 25 | |||
| Beta | 0.92 | |||
| Market Capitalization | 1.39 B | |||
| Total Asset | 1.24 B | |||
| Z Score | 6.6 | |||
| Net Asset | 1.24 B |
About Agios Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Agios Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agios Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agios Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Agios Stock
Agios Pharmaceuticals financial ratios help investors to determine whether Agios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Agios with respect to the benefits of owning Agios Pharmaceuticals security.